The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
Subscribe To Our Newsletter & Stay Updated
